Matching articles for "Zembrace"

Comparison Table: Triptans for Migraine (online only)

   
The Medical Letter on Drugs and Therapeutics • June 12, 2023;  (Issue 1678)
...
View the Comparison Table: Triptans for Migraine
Med Lett Drugs Ther. 2023 Jun 12;65(1678):e97-9 | Show Full IntroductionHide Full Introduction

Drugs for Migraine

   
The Medical Letter on Drugs and Therapeutics • June 12, 2023;  (Issue 1678)
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to...
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine pain without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine in most patients without vascular disease. Treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Med Lett Drugs Ther. 2023 Jun 12;65(1678):89-96 | Show Full IntroductionHide Full Introduction

Drugs for Migraine

   
The Medical Letter on Drugs and Therapeutics • October 5, 2020;  (Issue 1608)
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine headache without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to...
An oral nonopioid analgesic is often sufficient for acute treatment of mild to moderate migraine headache without severe nausea or vomiting. A triptan is the drug of choice for treatment of moderate to severe migraine headache pain in most patients without vascular disease. Early treatment of pain when it is still mild to moderate in intensity improves headache response and reduces the risk of recurrence.
Med Lett Drugs Ther. 2020 Oct 5;62(1608):153-60 | Show Full IntroductionHide Full Introduction

Lasmiditan (Reyvow) and Ubrogepant (Ubrelvy) for Acute Treatment of Migraine

   
The Medical Letter on Drugs and Therapeutics • March 9, 2020;  (Issue 1593)
Lasmiditan (Reyvow – Lilly), an oral serotonin (5-HT1F) receptor agonist, and ubrogepant (Ubrelvy – Allergan), an oral calcitonin gene-related peptide (CGRP) receptor antagonist, have been approved by...
Lasmiditan (Reyvow – Lilly), an oral serotonin (5-HT1F) receptor agonist, and ubrogepant (Ubrelvy – Allergan), an oral calcitonin gene-related peptide (CGRP) receptor antagonist, have been approved by the FDA for acute treatment of migraine with or without aura in adults.
Med Lett Drugs Ther. 2020 Mar 9;62(1593):35-9 | Show Full IntroductionHide Full Introduction

Comparison Table: Triptans for Migraine (online only)

   
The Medical Letter on Drugs and Therapeutics • February 13, 2017;  (Issue 1514)
...
View the Comparison Table: Triptans for Migraine
Med Lett Drugs Ther. 2017 Feb 13;59(1514):e27-9 | Show Full IntroductionHide Full Introduction